Local view for "http://purl.org/linkedpolitics/eu/plenary/2012-09-10-Speech-1-238-000"
| Predicate | Value (sorted: default) |
|---|---|
| rdf:type | |
| dcterms:Date | |
| dcterms:Is Part Of | |
| dcterms:Language | |
| lpv:document identification number |
"en.20120910.29.1-238-000"2
|
| lpv:hasSubsequent | |
| lpv:speaker | |
| lpv:spokenAs | |
| lpv:translated text |
"Madam President, I would like to express my esteem for the rapporteur and the shadow rapporteurs, who drafted two reports in a very short time, considering the urgent implementation of new legislation planned before the end of this year. I welcome the idea that the Commission and the European Medicines Agency bear more responsibility for the safety of pharmaceuticals. The agency’s broad mandate, which includes granting commercial licences to manufacturers, valid across the European Union, have been linked with the obligation to warn of dangers that have been detected but have not been the subject of state-level intervention. In the widely publicised case of a lethal drug in France, European institutions were, for many years, unable to have the drug prohibited in its country of origin while successive Member States withdrew it from the market. We know that there was a conflict of interest between the supervisory authority and the manufacturers of the medicine who financed it. We realise that the pharmaceutical companies are in too powerful a position. The battle is a difficult one, but victory remains possible and efforts should be continued."@en1
|
| lpv:videoURI |
Named graphs describing this resource:
The resource appears as object in 2 triples